Johns Hopkins ABX Guide
Dalbavancin
To view the entire topic, please log in or purchase a subscription.
Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:
-- The first section of this topic is shown below --
INDICATIONS
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
- S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)
NON-FDA APPROVED USES
No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)
-- To view the remaining sections of this topic, please log in or purchase a subscription --
INDICATIONS
FDA
- Treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organism.
- S. aureus(including MRSA), S. pyogenes, S. agalactiae, S. dysgalactiae, S. anginosus group, E. faecalis (vancomycin-susceptible)
NON-FDA APPROVED USES
No data on the use of dalbavancin for other infections, e.g., S. aureus infections (pneumonia, bacteremia, endocarditis)
There's more to see -- the rest of this topic is available only to subscribers.
